dra_schwartz / iStockphoto.com
29 March 2018Biotechnology
English appeals court overturns Regeneron transgenic mice decision
The English Court of Appeal has reversed a finding that two of Regeneron’s European patents covering transgenic mice were insufficient.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Biotechnology
3 February 2016 The English High Court has revoked two European patents owned by Regeneron Pharmaceuticals covering transgenic mice.
Biotechnology
24 June 2020 The UK Supreme Court today has sided with biopharmaceutical company Kymab, allowing its appeal in a suit involving Regeneron and patents covering transgenic mice.
Editor's picks
Editor's picks
Biotechnology
3 February 2016 The English High Court has revoked two European patents owned by Regeneron Pharmaceuticals covering transgenic mice.
Biotechnology
24 June 2020 The UK Supreme Court today has sided with biopharmaceutical company Kymab, allowing its appeal in a suit involving Regeneron and patents covering transgenic mice.
Biotechnology
3 February 2016 The English High Court has revoked two European patents owned by Regeneron Pharmaceuticals covering transgenic mice.
Biotechnology
24 June 2020 The UK Supreme Court today has sided with biopharmaceutical company Kymab, allowing its appeal in a suit involving Regeneron and patents covering transgenic mice.